Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 15/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 15/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26849923 | 1.00 | DDB1 (0.44) | DDB1CRBNGPR119CCR5 | |
| SCHEMBL21997902 | 0.95 | DDB1 (0.44) | DDB1CRBNGPR119CCR5 | |
| SCHEMBL21996773 | 0.93 | DDB1 (0.48) | DDB1CRBNGPR119 | |
| SCHEMBL30733887 | 0.92 | DDB1 (0.46) | DDB1CRBNGPR119 | |
| SCHEMBL21997979 | 0.91 | DDB1 (0.47) | DDB1CRBNGPR119CCR5 | |
| SCHEMBL21998073 | 0.90 | CCR5 (0.45) | DDB1CRBNGPR119CCR5 | |
| SCHEMBL21997653 | 0.89 | DDB1 (0.44) | DDB1CRBNCCR5 | |
| SCHEMBL21996732 | 0.89 | DDB1 (0.46) | DDB1CRBNGPR119CCR5 | |
| SCHEMBL21998172 | 0.89 | DDB1 (0.45) | DDB1CRBNGPR119CCR5 | |
| SCHEMBL26635042 | 0.89 | DDB1 (0.45) | DDB1CRBNGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404285-B2 | KRAS G12D proteolysis targeting chimeras | PAQ Therapeutics Inc. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4519273-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20250051364-A1 | KRAS G12D Proteolysis Targeting Chimeras | PAQ Therapeutics Inc. (US) | 2025-02-13 | — | — | US | disclosed |
| US-20240247000-A1 | KRAS G12D Proteolysis Targeting Chimeras | PAQ Therapeutics Inc. (US) | 2024-07-25 | — | — | US | disclosed |
| WO-2023215906-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | HANGZHOU JIJING PHARMACEUTICALTECHNOLOGY LIMITED (CN) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051364-A1 | KRAS G12D Proteolysis Targeting Chimeras | KRAS, NRAS, HRAS | DDB1 1063/4885CRBN 51/4885GPR119 2659/4885 |
| US-12404285-B2 | KRAS G12D proteolysis targeting chimeras | KRAS, NRAS, HRAS | DDB1 1063/4885CRBN 51/4885GPR119 2659/4885 |
| US-20240247000-A1 | KRAS G12D Proteolysis Targeting Chimeras | KRAS, NRAS, HRAS | DDB1 1063/4885CRBN 51/4885GPR119 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.